INDICATION

EVENITY™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More


The anabolic effect of EVENITY™ wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY™ use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close

EVENITY™ resources for patient care EVENITY™ resources for patient care

Help your patients get their EVENITY™ treatments

Locate alternative treatment sites where EVENITY™ can be administered to your patients.

VisitEvenityFinder.com
headset-iconheadset-icon

CONNECT TO AN EVENITY™ SALES REPRESENTATIVE TO REQUEST MATERIALS AND MORE.

To be connected to an EVENITY™ Sales Representative, please call 1-800-77-AMGEN (1-800-772-6436).

TELEMEDICINE CODING & RESOURCES

CMS GUIDANCE ON CPT AND HCPCS CODES

Medicare Telemedicine Healthcare Provider Fact Sheet

AMA GUIDANCE ON TELEMEDICINE CODING

AMA Quick Guide to Telemedicine in Practice

Important Notice: These links are external third-party websites not affiliated in any way with Amgen. By using these links, you will leave our website. They are being provided as a convenience and for informational purposes only, that they do not constitute an endorsement or an approval by Amgen or any of the products, services, or opinions of the organization or individual. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of any coverage or reimbursement for any product or service. Amgen bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH
EVENITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY™ should be discontinued.

Back to Top